SCHEMBL141930

SCHEMBL141930

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@H]1CN1CCOCC1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.90
FGFR1 P11362 10/20 0.90
MET P08581 8/20 0.90
PDGFRB P09619 8/20 0.90
SRC P12931 7/20 0.90
LCK P06239 6/20 0.90
YES1 P07947 6/20 0.90
PTK2B Q14289 3/20 0.90
KIT P10721 3/20 0.90
CDK2 P24941 2/20 0.90
MEN1 O00255 2/20 0.90
KMT2A Q03164 2/20 0.90
TDP1 Q9NUW8 2/20 0.90
PLK4 O00444 2/20 0.90
RIOK3 O14730 2/20 0.90
GAK O14976 2/20 0.90
DCLK1 O15075 2/20 0.90
EPHB6 O15197 2/20 0.90
MAP3K13 O43283 2/20 0.90
MAP3K7 O43318 2/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pha-665752 SCHEMBL93654 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL93656 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL93657 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL93655 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL29376386 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL140412 0.95 KDR (1.00) KDRFGFR1METPDGFRBSRC
SCHEMBL147331 0.94 KDR (0.91) KDRFGFR1METPDGFRBSRC
SCHEMBL6267151 0.94 KDR (0.91) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL15639801 0.94 KDR (0.99) KDRFGFR1METPDGFRBSRC
Pha-665752 SCHEMBL15639803 0.94 KDR (0.99) KDRFGFR1METPDGFRBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885MET 310/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885MET 310/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885MET 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.